CIK 0001785279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Metagenomi Therapeutics, Inc.
Sign in to watch- Ticker
- MGX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 813909017
- Phone
- (510) 871-4880
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
- Open-market buys, last 90 days
- $23,401
- in 1 filing
- Open-market sales, last 90 days
- $5,107
- in 3 filings
Net +$18,294. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-05 | Wapnick Pamela Chief Financial Officer | Sale | −6,265 | $2.88 | $18K | 63,051 |
| 2024-04-01 | Irish Jian See Remarks | Grant or award | +70,471 | 298,933 | ||
| 2024-04-01 | Irish Jian See Remarks | Grant or award · Stock Option (Right to Buy) | +296,308 | 296,308 | ||
| 2024-04-01 | Eckhardt Juergen Director | Grant or award · Stock Option (Right to Buy) | +78,636 | 78,636 | ||
| 2024-04-01 | Borges Luis Chief Scientific Officer | Grant or award | +69,316 | 69,316 | ||
| 2024-04-01 | Borges Luis Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +291,450 | 291,450 | ||
| 2024-04-01 | Wein Matthew See Remarks | Grant or award | +10,397 | 10,397 | ||
| 2024-04-01 | Wein Matthew See Remarks | Grant or award · Stock Option (Right to Buy) | +43,717 | 43,717 | ||
| 2024-04-01 | Wapnick Pamela Chief Financial Officer | Grant or award | +69,316 | 69,316 | ||
| 2024-04-01 | Wapnick Pamela Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +291,450 | 291,450 | ||
| 2024-04-01 | Noonberg Sarah B. Chief Medical Officer | Grant or award | +57,763 | 100,374 | ||
| 2024-04-01 | Noonberg Sarah B. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +242,875 | 242,875 | ||
| 2024-04-01 | Bernales Sebastian Director | Grant or award · Stock Option (Right to Buy) | +78,636 | 78,636 | ||
| 2024-04-01 | Harnest Simon See Remarks | Grant or award | +11,552 | 122,664 | ||
| 2024-04-01 | Harnest Simon See Remarks | Grant or award · Stock Option (Right to Buy) | +48,575 | 48,575 | ||
| 2024-04-01 | Delaney Simren See Remarks | Grant or award | +6,931 | 93,892 | ||
| 2024-04-01 | Delaney Simren See Remarks | Grant or award · Stock Option (Right to Buy) | +29,145 | 29,145 | ||
| 2024-04-01 | Dere Willard H Director | Grant or award · Stock Option (Right to Buy) | +78,636 | 78,636 | ||
| 2024-04-01 | Thomas Brian C. Chief Executive Officer | Grant or award | +118,992 | 2,496,276 | ||
| 2024-04-01 | Thomas Brian C. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +500,323 | 500,323 |
Page 4 of 6 · 101 trades